Explore more publications!

Press Releases

Public Health Action Network Is A Partnering Organization for the  'Healthy Indoor Air' Event at the UN General Assembly
WHO cautions of increase of chikungunya disease

WHO cautions of increase of chikungunya disease

Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
Hypersante Introduces the 2026 Longevity and Biohacking Summit in Paris
Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion
Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates
GBSA connects Pangyo’s innovative companies with global media outlets through the 2025 Pangyo Global Media Meet-Up
Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates
OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance -  Publication of Circular for Combined Annual General Meeting of  September 30, 2025
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
WHO cautions against increase of chikungunya illness

WHO cautions against increase of chikungunya illness

WHO Cautions Chikungunya Spread Threatens Billions

WHO Cautions Chikungunya Spread Threatens Billions

Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
Combined General Meeting of June 11, 2025
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®
Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA
Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
Deputy President Shipokosa Paulus Mashatile: Heritage Day 2025

Deputy President Shipokosa Paulus Mashatile: Heritage Day 2025

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions